首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

1378547

鴉片類藥物使用障礙市場：依藥物類型、給藥途徑、配銷通路和地區

Opioid Use Disorder Market, By Drug Type, By Route of Administration, By Distribution Channel, and By Region

出版日期: 2023年10月20日 | 出版商:

Coherent Market Insights | 英文 198 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2023年全球鴉片類藥物使用障礙市場規模為 32.4 億美元，預測期內（2023-2030年）CAGR為 8.7%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	32.4億美元
實績資料	2018-2021	預測期	2023-2030
預測期CAGR	8.70%	2030年市場規模預測	58億美元

圖 1.2023年全球市場佔有率（%）（依藥物類型）

天然存在或實驗室合成的鴉片類藥物，與身體和大腦神經細胞上的鴉片受體相互作用，有助於減輕疼痛。依藥物類別，包括處方止痛藥、合成鴉片類藥物和海洛因。處方鴉片類藥物用於治療急性疼痛，例如從受傷或手術中恢復、慢性疼痛、積極的癌症治療、安寧療護和臨終關懷。許多人在醫療監督下依賴處方鴉片類藥物。鴉片類藥物使用障礙是一種慢性、終生疾病，可能造成嚴重後果，包括殘疾、復發和死亡。美沙酮是一種完全鴉片受體促效劑，透過與大腦中的 mu-鴉片受體結合發揮作用，緩解癲癇發作和戒斷症狀。

美沙酮為液體形式，必須在醫療監督下每天給藥。這也降低了濫用和轉移的風險，這對一些患者來說仍然是一個挑戰。丁丙諾啡是一種部分鴉片促效劑，可緩解疼痛，但不會產生典型的欣快感。納曲酮是一種鴉片類藥物拮抗，這意味著它可以阻止其他鴉片類藥物的作用。口服製劑必須每天服用，而注射緩釋性只需每月服用一次即可保持療效。

市場動態

全球鴉片類藥物使用障礙市場的成長是由主要市場參與者增加產品推出以擴大產品系列的。例如，2021年12月，全球學名藥和生物學名藥領導者山德士宣布將分銷其授權學名藥Narcan （美國。在美國可透過零售藥局、醫院和其他機構購買。

本研究的主要特點

本報告對全球鴉片類藥物使用障礙市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR）。
它還強調了各個細分市場的潛在收益成長機會，並為該市場說明了一系列有吸引力的投資提案。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
根據公司亮點、產品系列、主要亮點、財務實績和策略等參數對全球鴉片類藥物使用障礙市場的主要參與者進行了分析。
本研究涵蓋的主要企業包括 Indivior PLC、Alkermes、Orexo AB、Titan Pharmaceuticals, Inc.、Teva Pharmaceutical Industries Ltd.、Mallinckrodt Pharmaceuticals、BioDelivery Sciences International Inc、Viatris Inc.、Hikma Pharmaceuticals PLC、Camurus AB、Sun Pharmacetical ., Amneal Pharmaceuticals LLC., Purdue Pharma LP, Alvogen, Faran Shimi Pharmaceutical, Novartis AG, Emplicure AB, MODASA Pharmaceuticals Pvt.
本報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
全球鴉片類藥物使用障礙市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球鴉片類藥物使用障礙市場的各種策略矩陣，促進相關人員的決策。

公司簡介
- Indivior PLC
- Alkermes
- Orexo AB
- Titan Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals
- BioDelivery Sciences International Inc.
- Viatris Inc.
- Hikma Pharmaceuticals PLC
- Camurus AB
- Sun Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC.
- Purdue Pharma LP
- Alvogen
- Faran Shimi Pharmaceutical
- Novartis AG
- Emplicure AB
- MODASA Pharmaceuticals Pvt. Ltd.
分析師觀點

第10章章節

參考
調查方法

簡介目錄

Product Code: CMI4597

Global opioid use disorder market is estimated to be valued at US$ 3.24 Bn in 2023, and is expected to exhibit a CAGR of 8.7% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 3.24 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	8.70%	2030 Value Projection:	US$ 5.8 Bn

Figure 1. Global Opioid Use Disorder Market Share (%), By Drug Type, 2023

Opioids are naturally or synthetically made in laboratories to interact with opioid receptors on the nerve cells in the body and brain, and helps in reducing pain. These are class of drugs that include prescription pain relievers, synthetic opioids, and heroin. Prescription opioids are used to treat acute pain such as recovering from injury or post-surgery, chronic pain, active-phase cancer treatment, palliative care, and end-of-life care. Many people rely on prescription opioids to manage their conditions under the care of a physician. Opioid use disorder is a chronic lifelong disorder, with serious potential consequences including disability, relapses, and death.

Methadone is a full opioid agonist that works by binding to the mu-opioid receptors in the brain to relieve cramps and withdrawal symptoms. It comes in a liquid form that must be administered daily under medical supervision. This makes it challenging for some patients but also reduces abuse and diversion risks. Buprenorphine is a partial opioid agonist that provides pain relief without the typical euphoria. Naltrexone is an opioid antagonist that blocks the effects of other opioids. The oral form must be taken daily while the injectable extended-release version lasts for monthly doses.

Market Dynamics

Global opioid use disorder market growth is driven by increasing product launches by key market players to expand their product portfolio. For instance, in December 2021, Sandoz, a global leader in generic and biosimilar medicines, announced the U.S. launch of its authorized generic of Narcan (naloxone hydrochloride) Nasal Spray 4mg that is used to reverse opioid overdose. It is available to people in the U.S. via retail pharmacies and institutions including hospitals.

Key features of the study:

This report provides an in-depth analysis of the global opioid use disorder market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global opioid use disorder market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Hikma Pharmaceuticals PLC, Camurus AB, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., Purdue Pharma LP, Alvogen, Faran Shimi Pharmaceutical, Novartis AG, Emplicure AB, and MODASA Pharmaceuticals Pvt. Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global opioid use disorder market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing global opioid use disorder market

Detailed Segmentation:

By Drug Type:
- Buprenorphine
- Methadone
- Naltrexone
- Others
By Route of Administration:
- Oral
- Parenteral
By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Indivior PLC
- Alkermes
- Orexo AB
- Titan Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals
- BioDelivery Sciences International Inc.
- Viatris Inc.
- Hikma Pharmaceuticals PLC
- Camurus AB
- Sun Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC.
- Purdue Pharma LP
- Alvogen
- Faran Shimi Pharmaceutical
- Novartis AG
- Emplicure AB
- MODASA Pharmaceuticals Pvt. Ltd.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Recent Test Launches
Product Launches/Approvals
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
PORTER's Analysis

4. Global Opioid Use Disorder Market, - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Opioid Use Disorder Market, By Drug Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Buprenorphine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Methadone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Naltrexone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

6. Global Opioid Use Disorder Market, By Route of Administration, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

7. Global Opioid Use Disorder Market, By Distribution Channel, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global Opioid Use Disorder Market, By Region, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Indivior PLC
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Alkermes
- Orexo AB
- Titan Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals
- BioDelivery Sciences International Inc.
- Viatris Inc.
- Hikma Pharmaceuticals PLC
- Camurus AB
- Sun Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC.
- Purdue Pharma LP
- Alvogen
- Faran Shimi Pharmaceutical
- Novartis AG
- Emplicure AB
- MODASA Pharmaceuticals Pvt. Ltd.
Analysts' Views